Amylin and amylin-amide lack an acute effect on blood glucose and insulin

M. A. Ghatei, H. K. Datta, M. Zaidi, D. Bretherton-Watt, S. J. Wimalawansa, I. MacIntyre, S. R. Bloom

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Amylin-amide has been implicated in the pathogenesis of type II diabetes due to its proposed inhibitory effect on insulin release from β cells of the pancreatic islets, and on glucose uptake by the skeletal muscle. In experiments with rats and rabbits we failed to demonstrate these anti-insulin actions of amylin and amylin-amide. A single bolus dose of the two peptides (500 pmol) administered i.v. failed to supress plasma insulin levels or to elevate blood glucose levels. The continuous infusion of amylin-amide into rabbits also failed to supress the release of insulin in response to hyperglycaemia produced by an i.v. bolus injection of glucose. These in vivo observations imply that the amylin peptides may not have a primary physiological role in carbohydrate metabolism, but in view of our previous findings, we speculate that the peptide has a more prominent role in calcium homeostasis.

Original languageEnglish
Pages (from-to)R9-R11
JournalJournal of Endocrinology
Volume124
Issue number2
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Dive into the research topics of 'Amylin and amylin-amide lack an acute effect on blood glucose and insulin'. Together they form a unique fingerprint.

Cite this